Series A · Biotech · Dublin, Ireland · Founded 2025 · 15–30 employees
Aerska is an Irish biotech company developing RNA interference therapeutics to treat neurological diseases like Alzheimer's and Parkinson's by crossing the blood-brain barrier. The company has raised significant funding including a $21 million seed round in 2025 and a $39 million Series A in early 2026, bringing total funds to approximately $60 million. Aerska uses proprietary 'brain shuttle' technology to deliver RNA medicines systemically to the central nervous system, addressing one of the biggest challenges in CNS drug development. Their precision medicine approach targets genetic forms of neurodegenerative diseases with antibody-oligo conjugate platforms that enable durable gene silencing in neurons.
No open roles listed right now.